# data[].attributes.body
The significant progress made in successfully treating many cancers is being undermined by the growing threat of drug-resistant infections or AMR.

# data[].attributes.body
Antimicrobial resistance poses a major threat to global human health.

# data[].attributes.body
Antimicrobial resistance is one of the top 10 global public health threats (source: WHO).

# data[].attributes.body
The misuse and overuse of antibiotics in humans, animals and plants are the main drivers in the development of drug-resistant infections.

# data[].attributes.attachment_link.authors[].name
Union for International Cancer Control (UICC)

# data[].attributes.attachment_link.title
Antimicrobial resistance (AMR): a growing threat to cancer care

# data[].attributes.body
Without stronger action, antimicrobial resistance is projected to lower global life expectancy by an average of 1.8 years by 2035. (source: Global Leaders Group (GLG) on AMR)

# data[].attributes.body
Infections are one of the most frequent complications in cancer treatments, with patients being three times more likely to die from a fatal infection compared to those without cancer (source: NIH).

# data[].attributes.body
Antibiotics and antifungals are an essential part of cancer treatment – many patients simply must take them. For their benefit it is important to better manage the use of these medicines and put in place key actions that can limit antimicrobial resistance.

# data[].attributes.body
There has been substantial progress in cancer care in the past decades, with key advances in surgery, radiotherapy, and medicines including immunotherapies. But the increasing inability of medicines to address certain infections can undermine all efforts to treat patients.